Valeant Pharmaceuticals International (NYSE:

) posted a loss in the third quarter. Valeant cut its full-year revenue forecast to a range of $5.7 billion to $5.9 billion, versus its earlier outlook of $5.8 billion to $6.2 billion. Valeant posted a quarterly loss of $973.2 million, or $2.92 per share, versus a year-ago profit of $7.6 million, or $0.02 per share. Excluding special items, its cash earnings climbed to $1.43 per share from $1.15 per share. Its revenue surged 74% to $1.54 billion. However, analysts were expecting earnings of $1.42 per share on revenue of $1.67 billion. Valeant shares fell 3.62% to $105.11 in pre-market trading.